Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KRRO Stock Forecast 2025-2026
$14.48
Current Price
$135.97M
Market Cap
Buy 10
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to KRRO Price Targets
+1,143.1%
To High Target of $180.00
+556.1%
To Median Target of $95.00
+266.0%
To Low Target of $53.00
KRRO Price Momentum
-6.9%
1 Week Change
+7.6%
1 Month Change
-71.8%
1 Year Change
-62.0%
Year-to-Date Change
-85.2%
From 52W High of $98.00
+30.1%
From 52W Low of $11.13
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Korro Bio (KRRO) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on KRRO and similar high-potential opportunities.
Latest KRRO Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, KRRO has a bullish consensus with a median price target of $95.00 (ranging from $53.00 to $180.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $14.48, the median forecast implies a 556.1% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 1,143.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KRRO Analyst Ratings
10
Buy
0
Hold
0
Sell
KRRO Price Target Range
Low
$53.00
Average
$95.00
High
$180.00
Current: $14.48
Latest KRRO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KRRO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 13, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $25.00 |
| May 13, 2025 | Oppenheimer | Andreas Argyrides | Outperform | Maintains | $90.00 |
| May 8, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $100.00 |
| Apr 29, 2025 | Cantor Fitzgerald | Steven Seedhouse | Overweight | Initiates | $74.00 |
| Apr 16, 2025 | Chardan Capital | Keay Nakae | Buy | Initiates | $25.00 |
| Mar 20, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $115.00 |
| Mar 19, 2025 | RBC Capital | Luca Issi | Outperform | Maintains | $95.00 |
| Nov 22, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $115.00 |
| Nov 18, 2024 | Jones Trading | Catherine Novack | Buy | Initiates | $130.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $115.00 |
| Oct 21, 2024 | Raymond James | Steven Seedhouse | Strong Buy | Initiates | $153.00 |
| Oct 21, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $105.00 |
| Oct 18, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $115.00 |
| Sep 19, 2024 | RBC Capital | Luca Issi | Outperform | Reiterates | $95.00 |
| Sep 17, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $100.00 |
| Aug 14, 2024 | William Blair | Myles Minter | Outperform | Initiates | $0.00 |
| Aug 14, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $100.00 |
| Aug 14, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $95.00 |
| May 21, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $100.00 |
| May 15, 2024 | BMO Capital | Kostas Biliouris | Outperform | Maintains | $120.00 |
Korro Bio Inc. (KRRO) Competitors
The following stocks are similar to Korro Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Korro Bio Inc. (KRRO) Financial Data
Korro Bio Inc. has a market capitalization of $135.97M with a P/E ratio of 0.0x. The company generates $4.82M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +12.3% quarter-over-quarter, while maintaining an operating margin of -981.2% and return on equity of -60.2%.
Valuation Metrics
Market Cap
$135.97M
Enterprise Value
$62.73M
P/E Ratio
0.0x
PEG Ratio
-1.4x
Price/Sales
28.2x
Growth & Margins
Revenue Growth (YoY)
+12.3%
Gross Margin
N/A
Operating Margin
-981.2%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+84.5%
Current Ratio
9.4x
Debt/Equity
32.5x
ROE
-60.2%
ROA
-29.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Korro Bio Inc. (KRRO) Business Model
About Korro Bio Inc.
What They Do
Innovates in RNA editing for genetic therapies.
Business Model
Korro Bio Inc. develops therapies aimed at correcting genetic mutations using advanced RNA editing technologies. The company generates revenue by creating solutions for a variety of genetic disorders, potentially transforming untreatable conditions into manageable health issues.
Additional Information
Operating in the biotechnology sector, Korro Bio is positioned at the forefront of genetic research and personalized medicine, contributing significantly to therapeutic development. The company's focus on innovation in genetic medicine makes it an important entity for investors interested in biotech advancements.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
104
CEO
Dr. Ram Aiyar MBA, Ph.D.
Country
United States
IPO Year
2019
Website
www.korrobio.comKorro Bio Inc. (KRRO) Latest News & Analysis
Latest News
Quick Summary
Korro Bio, Inc. (Nasdaq: KRRO) reported its Q1 2025 financial results and provided a business update on its RNA editing genetic medicines for various diseases.
Why It Matters
Korro Bio's financial results and business update signal progress in RNA editing technology, impacting investor sentiment and potential future valuations in biotech sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
1 month ago
Quick Summary
The company enhances its leadership by appointing GaoZhong Zhu, Ph.D. as SVP of CMC & Technical Operations and promoting Oliver Dolan to Principal Accounting Officer.
Why It Matters
Key leadership appointments can enhance a company's operational efficiency and strategic direction, potentially leading to improved financial performance and shareholder value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Korro Bio, Inc. (Nasdaq: KRRO) reported its 2024 financial results and updates on its RNA editing genetic medicines for various diseases on March 18, 2025.
Why It Matters
Korro Bio's financial results and updates on RNA editing developments highlight its growth potential, influencing stock performance and investor sentiment in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
2 months ago
Quick Summary
Korro Bio, Inc. (Nasdaq: KRRO) received FDA orphan drug designation for KRRO-110, aimed at treating Alpha-1 Antitrypsin Deficiency, enhancing its development prospects.
Why It Matters
Korro Bio's orphan drug designation for KRRO-110 enhances its market potential, attracts investment interest, and may lead to accelerated development and commercialization of the treatment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Korro Bio, Inc. (Nasdaq: KRRO) will present at the TD Cowen Health Care Conference on March 4, 2025. CEO Ram Aiyar and COO Todd Chappell will engage with investors at the event.
Why It Matters
Korro Bio's participation in a major healthcare conference highlights its visibility and engagement with investors, potentially influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The REWRITE study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of KRRO-110.
Why It Matters
The REWRITE study's focus on KRRO-110's safety and efficacy could impact its market potential, influencing stock prices and investment decisions in related biotech firms.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About KRRO Stock
What is Korro Bio Inc.'s (KRRO) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Korro Bio Inc. (KRRO) has a median price target of $95.00. The highest price target is $180.00 and the lowest is $53.00.
Is KRRO stock a good investment in 2025?
According to current analyst ratings, KRRO has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.48. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KRRO stock?
Wall Street analysts predict KRRO stock could reach $95.00 in the next 12 months. This represents a 556.1% increase from the current price of $14.48. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Korro Bio Inc.'s business model?
Korro Bio Inc. develops therapies aimed at correcting genetic mutations using advanced RNA editing technologies. The company generates revenue by creating solutions for a variety of genetic disorders, potentially transforming untreatable conditions into manageable health issues.
What is the highest forecasted price for KRRO Korro Bio Inc.?
The highest price target for KRRO is $180.00 from Yasmeen Rahimi at Piper Sandler, which represents a 1,143.1% increase from the current price of $14.48.
What is the lowest forecasted price for KRRO Korro Bio Inc.?
The lowest price target for KRRO is $53.00 from at , which represents a 266.0% increase from the current price of $14.48.
What is the overall KRRO consensus from analysts for Korro Bio Inc.?
The overall analyst consensus for KRRO is bullish. Out of 10 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $95.00.
How accurate are KRRO stock price projections?
Stock price projections, including those for Korro Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 16, 2025 3:50 AM UTC